KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Docetaxel
Related studies linked through entity extraction aliases.
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Perioperative Chemotherapy in Gastric Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE3
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
- Status
- TERMINATED
- Phase
- PHASE3
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
RegoNivo vs Standard of Care Chemotherapy in AGOC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
- Status
- RECRUITING
- Phase
- PHASE2
Study of Magrolimab in Patients With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
- Status
- RECRUITING
- Phase
- PHASE2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2